UCB Likely to Focus on Early-Stage Assets for Next Deals — Market Talk

UCB's portfolio offers growth potential into the next decade after the acquisitions of Candid Therapeutics and Neurona, so the Belgian drugmaker's next deals might target early-stage assets, Bank of America analysts say. Data due next year from a midstage trial of its galvokimig eczema drug candida…